TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells $930,266.86 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director Edward M. Basile sold 7,157 shares of the company’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $129.98, for a total transaction of $930,266.86. Following the transaction, the director now owns 1,193 shares of the company’s stock, valued at approximately $155,066.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

TransMedics Group Price Performance

NASDAQ TMDX opened at $127.22 on Thursday. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $132.96. The company has a market cap of $4.19 billion, a PE ratio of -374.18 and a beta of 1.87. The stock’s 50-day moving average price is $88.31 and its two-hundred day moving average price is $78.91.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The business had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. During the same quarter in the previous year, the business earned ($0.08) earnings per share. The firm’s revenue was up 132.9% compared to the same quarter last year. On average, analysts predict that TransMedics Group, Inc. will post 0.62 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have commented on TMDX. Oppenheimer raised their price target on shares of TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Canaccord Genuity Group upped their price objective on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Piper Sandler restated an “overweight” rating and set a $120.00 price target (up from $95.00) on shares of TransMedics Group in a research report on Wednesday, May 1st. Morgan Stanley lifted their price target on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. Finally, TD Cowen lifted their price objective on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Harbour Capital Advisors LLC lifted its position in shares of TransMedics Group by 1.7% in the fourth quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company’s stock worth $627,000 after purchasing an additional 140 shares in the last quarter. RiverPark Advisors LLC boosted its position in TransMedics Group by 19.5% during the fourth quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock valued at $104,000 after purchasing an additional 215 shares during the last quarter. First Horizon Advisors Inc. grew its stake in TransMedics Group by 26.8% in the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after purchasing an additional 222 shares in the last quarter. Park Avenue Securities LLC increased its position in TransMedics Group by 3.4% in the 1st quarter. Park Avenue Securities LLC now owns 11,374 shares of the company’s stock worth $841,000 after purchasing an additional 372 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in shares of TransMedics Group during the 1st quarter worth about $30,000. 99.67% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.